Analysis of Efficacy and Tolerability of Bruton Tyrosine Kinase Inhibitor Ibrutinib in Various B-cell Malignancies in General Community: a Single-Center Experience

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/j.clml.2016.07.077 ◽

2016 ◽

Vol 16 ◽

pp. S52-S53

Author(s):

Naveed Ali ◽

Syed Imran Mustafa Jafri ◽

Faizan Malik ◽

Mark Sundermeyer ◽

Peter Pickens

Keyword(s):

Tyrosine Kinase ◽

B Cell ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Single Center ◽

B Cell Malignancies ◽

Single Center Experience ◽

Bruton Tyrosine Kinase ◽

General Community

Download Full-text

Analysis of Efficacy and Tolerability of Bruton Tyrosine Kinase Inhibitor Ibrutinib in Various B-cell Malignancies in the General Community: A Single-center Experience

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/j.clml.2017.02.011 ◽

2017 ◽

Vol 17 ◽

pp. S53-S61 ◽

Cited By ~ 7

Author(s):

Naveed Ali ◽

Faizan Malik ◽

Syed Imran Mustafa Jafri ◽

Mary Naglak ◽

Mark Sundermeyer ◽

...

Keyword(s):

Tyrosine Kinase ◽

B Cell ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Single Center ◽

B Cell Malignancies ◽

Single Center Experience ◽

Bruton Tyrosine Kinase ◽

General Community

Download Full-text

Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-014-2617-3 ◽

2014 ◽

Vol 75 (1) ◽

pp. 111-121 ◽

Cited By ~ 34

Author(s):

Eleonora Marostica ◽

Juthamas Sukbuntherng ◽

David Loury ◽

Jan de Jong ◽

Xavier Woot de Trixhe ◽

...

Keyword(s):

Tyrosine Kinase ◽

B Cell ◽

Tyrosine Kinase Inhibitor ◽

Population Pharmacokinetic Model ◽

Pharmacokinetic Model ◽

Kinase Inhibitor ◽

Population Pharmacokinetic ◽

B Cell Malignancies ◽

Bruton Tyrosine Kinase

Download Full-text

Faculty Opinions recommendation of Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717959990.793469902 ◽

2013 ◽

Author(s):

Parameswaran Hari ◽

Robert Frank Cornell

Keyword(s):

Tyrosine Kinase ◽

B Cell ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Significant Activity ◽

B Cell Malignancies ◽

Bruton Tyrosine Kinase

Download Full-text

Faculty Opinions recommendation of Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717959990.793468443 ◽

2013 ◽

Author(s):

Kensei Tobinai

Keyword(s):

Tyrosine Kinase ◽

B Cell ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Significant Activity ◽

B Cell Malignancies ◽

Bruton Tyrosine Kinase

Download Full-text

Faculty Opinions recommendation of Targeting B-Cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718490094.793497269 ◽

2014 ◽

Author(s):

Stephan Stilgenbauer

Keyword(s):

Tyrosine Kinase ◽

B Cell ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Cell Receptor ◽

Anticancer Therapy ◽

B Cell Receptor ◽

B Cell Malignancies ◽

B Cell Receptor Signaling ◽

Cell Receptor Signaling

Download Full-text

A Study of Tyrosine Kinase Inhibitor ICP-022 in Patients With r/r B-Cell Malignancies

Case Medical Research ◽

10.31525/ct1-nct04014205 ◽

2019 ◽

Author(s):

Keyword(s):

Tyrosine Kinase ◽

B Cell ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

B Cell Malignancies

Download Full-text

Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3)

Case Medical Research ◽

10.31525/ct1-nct04148742 ◽

2019 ◽

Author(s):

Keyword(s):

Tyrosine Kinase ◽

B Cell ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Bruton Tyrosine Kinase

Download Full-text

Chemorefractory Diffuse Large B-Cell Lymphoma- is a Cure Possible with Bruton Tyrosine Kinase Inhibitor?

SSRN Electronic Journal ◽

10.2139/ssrn.3977261 ◽

2021 ◽

Author(s):

Purnima Sravanti Teegavarapu ◽

Monira Haque ◽

Andreia Barbieri ◽

Gustavo Rivero ◽

Martha Mims

Keyword(s):

Tyrosine Kinase ◽

B Cell ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Large B Cell Lymphoma ◽

Bruton Tyrosine Kinase ◽

Large B Cell

Download Full-text

Abstract 4634: Population pharmacokinetic model of ibrutinib, a Bruton's tyrosine kinase inhibitor, for the treatment of B-cell malignancies

10.1158/1538-7445.am2014-4634 ◽

2014 ◽

Author(s):

Eleonora Marostica ◽

Juthamas Sukbuntherng ◽

David Loury ◽

Jan D. Jong ◽

Xavier Woot de Trixhie ◽

...

Keyword(s):

Tyrosine Kinase ◽

B Cell ◽

Tyrosine Kinase Inhibitor ◽

Population Pharmacokinetic Model ◽

Pharmacokinetic Model ◽

Kinase Inhibitor ◽

Population Pharmacokinetic ◽

Bruton’S Tyrosine Kinase ◽

B Cell Malignancies ◽

Bruton's Tyrosine Kinase

Download Full-text

Phase I, first-in-human trial of Bruton’s tyrosine kinase inhibitor M7583 in patients with B-cell malignancies

Leukemia & Lymphoma ◽

10.1080/10428194.2021.1913139 ◽

2021 ◽

pp. 1-8

Author(s):

Wojciech Jurczak ◽

Simon Rule ◽

William Townsend ◽

David Tucker ◽

Barbara Sarholz ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

B Cell ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Bruton’S Tyrosine Kinase ◽

B Cell Malignancies ◽

Bruton's Tyrosine Kinase ◽

Human Trial

Download Full-text